Ali Asif

CFO Ali Asif sold 24.8K PTGX shares at $104.24 for $2.6M, reducing stake 29.0%; stock now -5.1% from 52-week high.

Ali Asif, Chief Financial Officer, executed a substantial sale of 24,765 shares (reducing his holding from 85,518 to 60,753 shares, a -29.0% reduction) at $104.24 on 2026-03-26 for a total value of $2,581,503.60. The current price of $98.97 is now -5.1% from the 52-week high of $104.31, and the stock is within 5% of where the CFO sold it. Looking at his same-ticker history at PTGX, his prior 90-day measurable outcome (sell on 2025-03-12) showed a -4.0% 90-day return—a pattern consistent with selling before declines. His cross-ticker track record shows a 100.00% well-timed rate on prior sells with an average 90-day return of -9.2%, indicating a consistent pattern of exiting before downturns across all holdings. Against a backdrop of severe fundamentals (annual revenue growth of -89.4%, latest-quarter revenue of $4.7M, net income of $-39.3M), the CFO's sale of nearly 30% of his stake warrants close monitoring of future quarterly results and operational developments.

CFO Ali Asif sold 46,203 shares at $83.13-$83.14 on 2026-01-27, reducing holdings by 43.4% to 60,320 shares; 100% of prior PTGX sells well-timed at 90-day mark.

Ali Asif, CFO of Protagonist Therapeutics, executed 2 separate sales totaling 46,203 shares for $3,841,037.42, bringing his holdings from 106,523 to 60,320 shares (-43.4%). The sale occurred as the stock trades at $83.08, down 12.9% from its 52-week high of $95.35 and down 6.4% over the past 30 days. His prior trading pattern at PTGX is notably disciplined: all 4 prior measurable sales at this ticker resulted in negative 90-day returns, meaning each sale preceded subsequent declines (100% well-timed rate at the 90-day mark). His cross-ticker sell track record similarly shows a 100% well-timed rate, with an average 90-day return of -9.2% after sales, suggesting consistent ability to exit before downturns. The company's fundamentals reflect a high-growth biotech profile (revenue +624.1% annual growth) alongside operational losses ($-39.3M net income on $4.7M quarterly revenue), with an elevated P/E of 113.81 relative to the current valuation of $5.2B market cap.

CFO Ali Asif sold 8,588 shares of PTGX at $82.48 (Jan 20). All 5 prior PTGX sells were well-timed 90d, but company posts $-39.3M net income on $4.7M revenue.

CFO Ali Asif sold 8.6K shares at $82.48 on 2026-01-20, reducing holdings by 9.9% to 78.1K shares. His timing history at PTGX is notably strong: all 5 prior sells at this ticker showed negative 90-day returns, indicating well-timed exits before subsequent declines. However, this sale occurs against a concerning financial backdrop—the latest quarter shows revenue of $4.7M against net income of $-39.3M, reflecting massive ongoing losses despite 624.1% annual revenue growth. The company's P/E of 114.92 suggests market pricing is heavily dependent on near-term execution. The insider's consistent pattern of well-timed sales at this specific ticker merits scrutiny, particularly when paired with fundamentals characterized by hypergrowth in a pre-profitable state where cash burn remains severe relative to revenue scale.

CFO Ali Asif sold 24,903 shares of PTGX at $58.73 for $1,462,553.19; stock is down 8.3% from 52-week high.

Ali Asif, Chief Financial Officer, sold 24,903 shares at $58.73, reducing his holdings by 28.4% from 87,724 to 62,821 shares. This sale occurred near the 52-week high of $59.76 (within 1% of the peak), consistent with his prior track record at PTGX: his 5 prior sells at this ticker were all well-timed at the 90-day mark, with negative 90-day returns ranging from -6.4% to -14.3%. The stock has since declined to $54.78, marking a -8.3% retreat from its 52-week high, aligning with the historical pattern. Protagonist Therapeutics faces significant headwinds: the company posted a quarterly net loss of $33,210,000.00 against revenue of only $4,675,000.00, indicating severe cash burn despite 624.1% annual revenue growth. The CFO's substantial reduction in ownership—selling at the cycle peak while losses remain acute—warrants careful observation of near-term cash flow and clinical progress.

CFO Ali Asif sold 14,203 shares ($631.9K) at $44.49 avg; stock at $47.02; all 4 prior PTGX sales were 90d well-timed.

Ali Asif, CFO, executed 2 separate sales totaling 14,203 shares for $631,871.77, reducing his holdings by 28.9% from 49,163 to 34,960 shares. The sales occurred at an average price of $44.49, while the current price stands at $47.02, representing a near-peak market level (0.0% from 52-week high). Asif's prior trade history at PTGX shows 4 of 4 preceding sales were well-timed at the 90-day mark, with cumulative post-sale declines ranging from 5.5% to 14.3%. His cross-ticker track record reflects a 100.00% well-timed rate on 4 prior sells with a 90-day average return of -11.8%, indicating a consistent pattern of selling ahead of downside. The company's fundamentals reveal significant cash burn ($30.6M net loss in the latest full fiscal year) paired with strong revenue growth (+125.7% annually), though profitability remains distant; the current market cap of $2.8B against quarterly revenue of only $4.2M creates valuation tension. This sale by a senior financial officer, consistent with his established pattern of well-timed exits at this ticker, merits investor attention as a potential signal of internal capital allocation concerns.